전체기사보기
날짜선택-
-
[단독] McDonald’s halts US reopening plans amid coronavirus surge
- [단독] McDonald’s halts US reopening plans amid coronavirus surge McDonald’s has halted plans to reopen its dining rooms amid a surge in coronavirus infections. The fast-food giant will not resume dine-in service at any more US restaurants for three weeks as the number of COVID-19 cases continues to climb, the company said in a Wednesday letter. “This surge shows nobody is exempt from this virus — even places that previously had very few cases,” McDonald’s USA President Joe Erlinger and Mark Salebra, chair of the National Franchisee Leadership Alliance, wrote in the letter viewed by The Post. “Moving forward, we will continue to monitor the situation and adjust as needed to protect the safety of our employees and customers.” Roughly 2,200 of McDonald’s 14,000 US locations have already reopened their dining rooms. Dine-in service can continue in places that allow it, the letter says, though the company advised restaurant owners and operators to review any new guidance from government officials. The Wall Street Journal first reported on the change. The move came as several states ordered restaurants and bars to close or scale back service as they grappled with the jump in infections. The US on Wednesday recorded more than 50,000 COVID-19 cases for the first time since the pandemic began, according to Johns Hopkins University data. McDonald’s global comparable sales plunged nearly 30 percent year-over-year in April and May as the vast majority of its restaurants were limited to carry-out, drive-through and delivery service, the company said in a June 16 regulatory filing. The Chicago-based chain announced plans last month to hire roughly 260,000 restaurant employees this summer as the US began to emerge from its economic lockdown. It’s uncertain how the pause on reopening dining rooms will affect those plans.
-
- Animal Rights
-
[단독] McDonald’s halts US reopening plans amid coronavirus surge
-
-
[단독외신] Coty changes CEO again, hires former L’Oreal executive
- [단독외신]Coty changes CEO again, hires former L’Oreal executive Coty on Thursday named former L’Oreal executive Sue Nabi as chief executive officer, the cosmetics maker’s fifth since its multibillion-dollar deal with Procter & Gamble nearly five years ago. The company’s shares, which have lost more than 60 percent this year, rose about 5 percent in early trading, although they were up only 1.1 percent shortly after noon. Nabi will take over from Peter Harf, who was appointed to the top job in June, a move that placed the fortunes of the company squarely in the hands of its largest shareholder JAB Holdings, in which Harf is a partner. Harf was brought in to rescue the company from a series of CEO departures after years of slowing sales and mounting debt as it struggled to integrate the brands acquired from Procter & Gamble. “This was unexpected… We thought Harf would stay,” D.A. Davidson analyst Linda Bolton Weiser said. Harf will remain with Coty as its executive chairman and Nabi, the company’s first female CEO, will take over on Sept. 1, the company said. Nabi, who has been credited for reviving L’Oreal’s makeup brand Lancôme, faces an uphill task of rescuing Coty’s sales and steering it through the coronavirus crisis. She is also the founder of a vegan and ultra-luxury skincare brand, a category where Coty is trying to focus. “The most important takeaway is that Nabi brings a lengthy Beauty background, something that has been lacking with prior CEOs,” Wells Fargo analyst Joe Lachky said. The company has been trying to streamline its business and partner with brands endorsed by celebrities with huge social media following to make its products resonate better with millennial customers.
-
- Animal Rights
-
[단독외신] Coty changes CEO again, hires former L’Oreal executive
-
-
[단독외신] Smiths Detection enters into agreement to acquire PathSensors to expand its biological-detection capability
- [단독외신] Smiths Detection enters into agreement to acquire PathSensors to expand its biological-detection capability Smiths Detection, a global leader in detection and screening technologies, today announces that it has entered into an agreement to acquire PathSensors, a leading bio-technology solutions and environmental-testing company based in Baltimore, MD. The acquisition expands Smiths Detection’s sensing capabilities across the CBRNE (chemical, biological, radiological, nuclear and explosive) spectrum to respond quickly to emerging threats. PathSensors provides high-speed, highly sensitive pathogen-detection and biothreat solutions and has developed a robust fieldable method of identifying biological threats in minutes. The company shares a similar customer base to that which Smiths Detection serves for chemical-threat detection, while also offering an expanded end-use market into adjacent security markets such as food and agricultural safety. PathSensors offers multiple assays that are already available, at an independently verified speed and sensitivity data, which offer an opportunity to develop their future potential. The transaction will enable Smiths Detection to accelerate its position in biological-detection capabilities which are important both within our current markets and beyond. “The acquisition of PathSensors will allow us to broaden our detection capabilities within the biological spectrum, which is becoming more relevant in the current environment,” said Roland Carter, President of Smiths Detection. “This is consistent with our approach to increase our focus on investing selectively in technology and innovation for the purpose of getting closer to our customers and expanding into new markets.” The contract is subject to customary closing conditions and is expected to conclude within the next four weeks.
-
- Animal Rights
-
[단독외신] Smiths Detection enters into agreement to acquire PathSensors to expand its biological-detection capability
-
-
[단독외신] EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome
- EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said: “Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production - the so-called ‘cytokine storm’ - with IL-6 recognized as a key driver of this severe condition. Treatment approaches neutralizing IL-6 could therefore play a key role in mitigating further detrimental inflammation and progression to respiratory failure, which can be fatal. We thank the FDA for recognizing the importance of this clinical trial and the quick approval we received. Our plan now is to initiate the study as quickly as possible with the hope of seeing improved clinical outcomes in these critically ill patients.” To date, several independent clinical trials have begun globally to explore the safety and efficacy of siltuximab for the treatment of severe COVID-19 patients. Final results from the Papa Giovanni XXIII Hospital sponsored SISCO[1] (Siltuximab In Serious COVID-19) Study, an observational cohort control trial investigating siltuximab plus standard of care in COVID-19 patients with serious respiratory complications, are available via pre-print summary here (https://bit.ly/3ioH9vW).[2] However, the newly approved confirmatory clinical trial is vital because these findings require validation in a well-controlled randomized study and there is limited published data on the safety and efficacy of siltuximab in COVID-19. Siltuximab is also not yet FDA-approved for complications associated with COVID-19.
-
- Animal Rights
-
[단독외신] EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome